Method for identifying natural antigen peptide extracted from tissue by using HLA-I candidate peptide library

Abstract

The invention discloses a method for identifying natural antigen peptide extracted from tissue by using an HLA-I candidate peptide library. The method comprises the following steps: S1, constructing the HLA-I candidate peptide library; S2, identifying the HLA-I type molecule related peptide compound by high-throughput mass spectrometry; S3, identifying the HLA-I type molecule related peptide compound based on the HLA-I candidate peptide library; S4, identifying the HLA-I genotype of the sample; and S5, screening an HLA-I type molecule related immune peptide group based on the binding force of the candidate peptide and the HLA-I type molecule. According to the method, the blank of a special database for identifying the immune peptide group by mass spectrometry is filled, and the problems of overlarge search space and high error occurrence rate during high-throughput mass spectrometry identification of the HLA-I type molecule related peptide group due to database mismatching are solved; the clinical difficulty caused by HLA-I genotype polymorphism distribution of a patient is overcome, and individualized identification of an immune peptide group is realized; the method effectively improves the accuracy and efficiency of high-throughput mass spectrum identification of HLA-I type molecule related immune peptide groups, provides an efficient and reliable method for research and development of tumor individualized therapeutic vaccines, and has very high clinical practical value.

Description

technical field [0001] The invention relates to the technical field of molecular biology, in particular to a method for identifying natural antigen peptides extracted from tissues by using an HLA-I candidate peptide library. Background technique [0002] Immunotherapy is a research hotspot in tumor treatment, and therapeutic vaccines have attracted much attention due to their targeting and safety characteristics. The immune system accurately recognizes and kills tumor cells through tumor-specific or related antigens. Tumor therapeutic vaccines are designed to activate or enhance the body's specific immune response against tumor antigens, and then target and eliminate tumor cells. At present, FDA has approved the marketing of therapeutic vaccines for prostate cancer and melanoma, and obtained safe and effective clinical effects, confirming the value and prospect of therapeutic vaccines. [0003] A key issue in the development of therapeutic tumor vaccines is the identificat...

AI Technical Summary

Problems solved by technology

[0005] HLA-I alleles are highly polymorphic, and the cost of establishing a personalized peptidome database for each sample is too high, which is not conducive to clinical promotion

At the same time, in order to avoid too large invalid search space, it is not suitable to include all short peptides that may bind to HLA-I molecules in the peptide group database

Images